<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00824850</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-3016</org_study_id>
    <secondary_id>B1851014</secondary_id>
    <nct_id>NCT00824850</nct_id>
  </id_info>
  <brief_title>Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort</brief_title>
  <acronym>PILOT</acronym>
  <official_title>Characterization of the Prevnar Infant Long-term Immune Response vs a Prevnar Naive Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the &quot;late&quot; immune response to further doses of
      pneumococcal conjugate vaccine more than 10 years after primary immunization with Prevnar
      (7vPnC) in infancy, as compared with individuals who did not receive Prevnar in infancy (the
      Prevnar naive cohort which received MnCC). The study will take place at a single study
      center. Study participants must have participated previously in a specific Wyeth Prevnar
      study (Study D118-P8) and must still be enrolled in the Northern California Kaiser Permanente
      (NCKP) health plan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 Mcg/mL for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)</measure>
    <time_frame>Day 28 (Visit 5)</time_frame>
    <description>Percentage of participants achieving predefined IgG antibody threshold ≥0.35 micrograms per milliliter (Mcg/mL) for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% confidence intervals (CIs) based on the observed percentage of participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 Mcg/mL for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)</measure>
    <time_frame>Day 7 (Visit 4)</time_frame>
    <description>Percentage of participants achieving predefined IgG antibody threshold ≥0.35 Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥LLOQ for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)</measure>
    <time_frame>Day 28 (Visit 5)</time_frame>
    <description>Percentage of participants achieving predefined OPA antibody titer ≥ serotype-specific lower limit of quantification (LLOQ) using modified microcolony assays for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. LLOQ for each serotype: 1=1:8, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥LLOQ for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)</measure>
    <time_frame>Day 7 (Visit 4)</time_frame>
    <description>Percentage of participants achieving predefined OPA antibody titer ≥ serotype-specific lower limit of quantification (LLOQ) using modified microcolony assays for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. LLOQ for each serotype: 1=1:8, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥1:8 for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)</measure>
    <time_frame>Day 28 (Visit 5)</time_frame>
    <description>Percentage of participants achieving predefined OPA antibody titer ≥1:8 for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. The lowest titer that can be determined using the standard OPA assay is a titer of 1:8 limit of detection (LOD) and is the same for each serotype-specific OPA assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥1:8 for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)</measure>
    <time_frame>Day 7 (Visit 4)</time_frame>
    <description>Percentage of participants achieving predefined OPA antibody titer ≥1:8 for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. The lowest titer that can be determined using the standard OPA assay is a titer of 1:8 limit of detection (LOD) and is the same for each serotype-specific OPA assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5</measure>
    <time_frame>Baseline (Visit 1), Day 28 (Visit 5)</time_frame>
    <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5</measure>
    <time_frame>Baseline (Visit 1), Day 28 (Visit 5)</time_frame>
    <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4</measure>
    <time_frame>Baseline (Visit 1), Day 7 (Visit 4)</time_frame>
    <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4</measure>
    <time_frame>Baseline (Visit 1), Day 7 (Visit 4)</time_frame>
    <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5</measure>
    <time_frame>Baseline (Visit 1), Day 28 (Visit 5)</time_frame>
    <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5</measure>
    <time_frame>Baseline (Visit 1), Day 28 (Visit 5)</time_frame>
    <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4</measure>
    <time_frame>Baseline (Visit 1), Day 7 (Visit 4)</time_frame>
    <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4</measure>
    <time_frame>Baseline (Visit 1), Day 7 (Visit 4)</time_frame>
    <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 5)</measure>
    <time_frame>Day 28 (Visit 5)</time_frame>
    <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 4)</measure>
    <time_frame>Day 7 (Visit 4)</time_frame>
    <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 5)</measure>
    <time_frame>Day 28 (Visit 5)</time_frame>
    <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 4)</measure>
    <time_frame>Day 7 (Visit 4)</time_frame>
    <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Pneumococcal Conjugate Vaccine</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Prevnar in study D118-P8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received MnCC in study D118-P8</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>single injection, single dose, single site, 0.5 mL per dose.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>13vPnC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>single injection, single dose, single site, 0.5 mL per dose.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>13vPnC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fully vaccinated per-protocol (4 doses of vaccine given at 2, 4, 6, and 12-15 months
             of age) subjects enrolled in the Prevnar arm of Study D118-P8, OR

          -  Fully vaccinated per-protocol subjects from the control arm of the same study that did
             not receive Prevnar after the close of Study D118-P8, or at any time following the
             study, AND

          -  Still enrolled in NCKP health plan.

          -  Subjects included in either group above must be in good health as determined by
             medical history, physical examination, and clinical judgment.

        Exclusion Criteria:

          -  Previous receipt of pneumococcal polysaccharide vaccine.

          -  History of documented recurrent pneumococcal otitis media or any occurence of
             pneumonia within past 12 months

          -  History of documented invasive pneumococcal disease (defined as a positive culture of
             S. pneumoniae from a normally sterile body site).

          -  Known or suspected disease or dysfunction of the immune system, including:

          -  HIV infection

          -  Malignancy

          -  Receipt of immunosuppressive therapy

          -  Sickle cell hemoglobinopathy

          -  Concomitant vaccination during the study period.

          -  Known hypersensitivity to any component of Prevnar.

          -  Any major illness/condition that, in the investigator's judgment, will substantially
             increase the risk associated with the subject's participation in and completion of,
             the study, or could preclude the evaluation of the subject's response.

          -  Receipt of immune globulin within the past 3 months.

          -  Positive pregnancy test for menarchal female subjects.

          -  Females who are breastfeeding.

          -  For control subjects, previous receipt of Prevnar at any time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hayward</city>
        <state>California</state>
        <zip>94545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6096A1-3016&amp;StudyName=Study%20Evaluating%20Prevnar%20Infant%20Long-term%20Immune%20Response%20versus%20Prevnar%20Naive%20Cohort</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2009</study_first_submitted>
  <study_first_submitted_qc>January 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2009</study_first_posted>
  <results_first_submitted>August 4, 2011</results_first_submitted>
  <results_first_submitted_qc>October 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 11, 2011</results_first_posted>
  <last_update_submitted>October 5, 2011</last_update_submitted>
  <last_update_submitted_qc>October 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single site</keyword>
  <keyword>single dose</keyword>
  <keyword>Participated in Wyeth D118-P8</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were previously enrolled in Prevnar protocol D118-P8 (study duration 1995 to 1998) and were randomized to receive either 7-valent pneumococcal conjugate vaccine or meningococcal C conjugate vaccine in that study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>7vPnC / 13vPnC</title>
          <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
        </group>
        <group group_id="P2">
          <title>MnCC / 13vPnC</title>
          <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 13vPnC</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>7vPnC / 13vPnC</title>
          <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
        </group>
        <group group_id="B2">
          <title>MnCC / 13vPnC</title>
          <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.6" spread="1.1"/>
                    <measurement group_id="B2" value="13.1" spread="0.9"/>
                    <measurement group_id="B3" value="12.8" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 Mcg/mL for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)</title>
        <description>Percentage of participants achieving predefined IgG antibody threshold ≥0.35 micrograms per milliliter (Mcg/mL) for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% confidence intervals (CIs) based on the observed percentage of participants.</description>
        <time_frame>Day 28 (Visit 5)</time_frame>
        <population>Evaluable Immunogenicity population: eligible participants based on all inclusion and exclusion criteria, had a baseline blood sample collection performed (Visit 1), received 1 dose of 13vPnC, and had Visit 5 blood sample collection performed, and at least 1 valid and determinate assay result at Visit 1 and also at Visit 5.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 Mcg/mL for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)</title>
          <description>Percentage of participants achieving predefined IgG antibody threshold ≥0.35 micrograms per milliliter (Mcg/mL) for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% confidence intervals (CIs) based on the observed percentage of participants.</description>
          <population>Evaluable Immunogenicity population: eligible participants based on all inclusion and exclusion criteria, had a baseline blood sample collection performed (Visit 1), received 1 dose of 13vPnC, and had Visit 5 blood sample collection performed, and at least 1 valid and determinate assay result at Visit 1 and also at Visit 5.</population>
          <units>observed percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97.1" lower_limit="85.1" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="82.3" upper_limit="99.4"/>
                    <measurement group_id="O2" value="97.0" lower_limit="84.2" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>14.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.7</ci_lower_limit>
            <ci_upper_limit>10.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 Mcg/mL for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)</title>
        <description>Percentage of participants achieving predefined IgG antibody threshold ≥0.35 Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants.</description>
        <time_frame>Day 7 (Visit 4)</time_frame>
        <population>Evaluable Immunogenicity population; N=number of participants with a determinate IgG antibody concentration for the serotypes.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Pneumococcal IgG Antibody Concentration ≥0.35 Mcg/mL for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)</title>
          <description>Percentage of participants achieving predefined IgG antibody threshold ≥0.35 Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants.</description>
          <population>Evaluable Immunogenicity population; N=number of participants with a determinate IgG antibody concentration for the serotypes.</population>
          <units>observed percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="82.3" upper_limit="99.4"/>
                    <measurement group_id="O2" value="85.7" lower_limit="69.7" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97.1" lower_limit="85.1" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="94.3" lower_limit="80.8" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="86.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="94.3" lower_limit="80.8" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97.1" lower_limit="85.1" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="82.3" upper_limit="99.4"/>
                    <measurement group_id="O2" value="87.9" lower_limit="71.8" upper_limit="96.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>9.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>25.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>14.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>19.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>17.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>14.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>6.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.4</ci_lower_limit>
            <ci_upper_limit>23.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥LLOQ for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)</title>
        <description>Percentage of participants achieving predefined OPA antibody titer ≥ serotype-specific lower limit of quantification (LLOQ) using modified microcolony assays for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. LLOQ for each serotype: 1=1:8, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.</description>
        <time_frame>Day 28 (Visit 5)</time_frame>
        <population>Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the serotypes.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥LLOQ for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)</title>
          <description>Percentage of participants achieving predefined OPA antibody titer ≥ serotype-specific lower limit of quantification (LLOQ) using modified microcolony assays for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. LLOQ for each serotype: 1=1:8, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.</description>
          <population>Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the serotypes.</population>
          <units>observed percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="86.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97.1" lower_limit="84.7" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="75.2" upper_limit="97.1"/>
                    <measurement group_id="O2" value="88.6" lower_limit="73.3" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="86.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: difference in proportions, [7vPnC / 13vPnC) - (MnCC / 13vPnC), expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.2</ci_lower_limit>
            <ci_upper_limit>10.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.9</ci_lower_limit>
            <ci_upper_limit>8.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>15.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.0</ci_lower_limit>
            <ci_upper_limit>17.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.9</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥LLOQ for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)</title>
        <description>Percentage of participants achieving predefined OPA antibody titer ≥ serotype-specific lower limit of quantification (LLOQ) using modified microcolony assays for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. LLOQ for each serotype: 1=1:8, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.</description>
        <time_frame>Day 7 (Visit 4)</time_frame>
        <population>Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the serotypes.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥LLOQ for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)</title>
          <description>Percentage of participants achieving predefined OPA antibody titer ≥ serotype-specific lower limit of quantification (LLOQ) using modified microcolony assays for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. LLOQ for each serotype: 1=1:8, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.</description>
          <population>Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the serotypes.</population>
          <units>observed percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="86.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3" lower_limit="80.8" upper_limit="99.3"/>
                    <measurement group_id="O2" value="97.1" lower_limit="84.7" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" lower_limit="85.8" upper_limit="99.9"/>
                    <measurement group_id="O2" value="94.3" lower_limit="80.8" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97.1" lower_limit="85.1" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="86.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="75.2" upper_limit="97.1"/>
                    <measurement group_id="O2" value="88.2" lower_limit="72.5" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97.0" lower_limit="84.2" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="86.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: difference in proportions, [7vPnC / 13vPnC) - (MnCC / 13vPnC), expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.9</ci_lower_limit>
            <ci_upper_limit>8.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.2</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.8</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>16.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>15.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.9</ci_lower_limit>
            <ci_upper_limit>8.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.8</ci_lower_limit>
            <ci_upper_limit>18.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>15.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.9</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5</title>
        <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
        <time_frame>Baseline (Visit 1), Day 28 (Visit 5)</time_frame>
        <population>Evaluable Immunogenicity population. GMCs calculated using all participants with available data at both the prevaccination and postvaccination blood draws.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC Prevaccination Visit 1</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC / 13vPnC Postvaccination Visit 5</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5</title>
          <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
          <population>Evaluable Immunogenicity population. GMCs calculated using all participants with available data at both the prevaccination and postvaccination blood draws.</population>
          <units>Mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="0.12" upper_limit="0.33"/>
                    <measurement group_id="O2" value="5.96" lower_limit="4.10" upper_limit="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.89" lower_limit="4.61" upper_limit="7.51"/>
                    <measurement group_id="O2" value="66.72" lower_limit="50.19" upper_limit="88.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" lower_limit="1.19" upper_limit="2.00"/>
                    <measurement group_id="O2" value="8.62" lower_limit="6.55" upper_limit="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" lower_limit="0.39" upper_limit="0.86"/>
                    <measurement group_id="O2" value="41.45" lower_limit="27.72" upper_limit="61.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.48" upper_limit="1.18"/>
                    <measurement group_id="O2" value="5.93" lower_limit="4.34" upper_limit="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" lower_limit="2.08" upper_limit="4.15"/>
                    <measurement group_id="O2" value="13.41" lower_limit="8.89" upper_limit="20.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" lower_limit="1.92" upper_limit="3.27"/>
                    <measurement group_id="O2" value="17.20" lower_limit="12.44" upper_limit="23.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.71" upper_limit="1.54"/>
                    <measurement group_id="O2" value="11.59" lower_limit="7.34" upper_limit="18.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" lower_limit="0.83" upper_limit="2.04"/>
                    <measurement group_id="O2" value="2.19" lower_limit="1.60" upper_limit="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" lower_limit="2.45" upper_limit="4.27"/>
                    <measurement group_id="O2" value="6.80" lower_limit="4.75" upper_limit="9.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" lower_limit="2.85" upper_limit="5.03"/>
                    <measurement group_id="O2" value="29.11" lower_limit="19.04" upper_limit="44.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" lower_limit="0.93" upper_limit="2.05"/>
                    <measurement group_id="O2" value="9.92" lower_limit="7.03" upper_limit="14.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.05" lower_limit="5.52" upper_limit="8.99"/>
                    <measurement group_id="O2" value="21.29" lower_limit="14.90" upper_limit="30.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: Geometric mean fold rises (GMFRs) were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>29.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.61</ci_lower_limit>
            <ci_upper_limit>49.33</ci_upper_limit>
            <estimate_desc>Confidence intervals (CI) for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>11.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.49</ci_lower_limit>
            <ci_upper_limit>15.13</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>5.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.06</ci_lower_limit>
            <ci_upper_limit>7.67</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>71.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>40.74</ci_lower_limit>
            <ci_upper_limit>124.08</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>7.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.92</ci_lower_limit>
            <ci_upper_limit>12.73</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>4.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.87</ci_lower_limit>
            <ci_upper_limit>7.26</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>6.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.51</ci_lower_limit>
            <ci_upper_limit>10.42</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>11.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.98</ci_lower_limit>
            <ci_upper_limit>17.64</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.37</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>2.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.52</ci_lower_limit>
            <ci_upper_limit>2.90</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>7.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.77</ci_lower_limit>
            <ci_upper_limit>12.42</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>7.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.95</ci_lower_limit>
            <ci_upper_limit>10.48</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>3.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.23</ci_lower_limit>
            <ci_upper_limit>4.10</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5</title>
        <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
        <time_frame>Baseline (Visit 1), Day 28 (Visit 5)</time_frame>
        <population>Evaluable Immunogenicity population; GMCs calculated using all participants with available data at both the prevaccination and postvaccination blood draws.</population>
        <group_list>
          <group group_id="O1">
            <title>MnCC / 13vPnC Prevaccination Visit 1</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC Postvaccination Visit 5</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5</title>
          <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
          <population>Evaluable Immunogenicity population; GMCs calculated using all participants with available data at both the prevaccination and postvaccination blood draws.</population>
          <units>Mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.07" upper_limit="0.29"/>
                    <measurement group_id="O2" value="2.86" lower_limit="2.00" upper_limit="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" lower_limit="2.78" upper_limit="5.67"/>
                    <measurement group_id="O2" value="22.62" lower_limit="14.56" upper_limit="35.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.20" upper_limit="2.38"/>
                    <measurement group_id="O2" value="4.70" lower_limit="3.49" upper_limit="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" lower_limit="0.43" upper_limit="1.43"/>
                    <measurement group_id="O2" value="18.50" lower_limit="10.10" upper_limit="33.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.46" upper_limit="1.13"/>
                    <measurement group_id="O2" value="9.79" lower_limit="6.43" upper_limit="14.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" lower_limit="1.32" upper_limit="3.05"/>
                    <measurement group_id="O2" value="18.02" lower_limit="11.56" upper_limit="28.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" lower_limit="1.70" upper_limit="3.14"/>
                    <measurement group_id="O2" value="20.80" lower_limit="13.07" upper_limit="33.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" lower_limit="0.43" upper_limit="1.15"/>
                    <measurement group_id="O2" value="5.30" lower_limit="3.40" upper_limit="8.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" lower_limit="0.73" upper_limit="1.86"/>
                    <measurement group_id="O2" value="1.81" lower_limit="1.25" upper_limit="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" lower_limit="2.77" upper_limit="5.31"/>
                    <measurement group_id="O2" value="7.39" lower_limit="4.98" upper_limit="10.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" lower_limit="2.79" upper_limit="5.23"/>
                    <measurement group_id="O2" value="17.05" lower_limit="10.82" upper_limit="26.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="0.73" upper_limit="1.72"/>
                    <measurement group_id="O2" value="5.94" lower_limit="4.08" upper_limit="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.18" lower_limit="4.57" upper_limit="8.35"/>
                    <measurement group_id="O2" value="20.17" lower_limit="15.28" upper_limit="26.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>19.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.99</ci_lower_limit>
            <ci_upper_limit>38.77</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>5.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.90</ci_lower_limit>
            <ci_upper_limit>8.33</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>2.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.16</ci_lower_limit>
            <ci_upper_limit>3.57</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>23.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.17</ci_lower_limit>
            <ci_upper_limit>41.79</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>13.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.94</ci_lower_limit>
            <ci_upper_limit>20.92</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>8.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.21</ci_lower_limit>
            <ci_upper_limit>12.97</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>9.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.91</ci_lower_limit>
            <ci_upper_limit>13.72</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>7.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.36</ci_lower_limit>
            <ci_upper_limit>10.72</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.30</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.43</ci_lower_limit>
            <ci_upper_limit>2.60</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>4.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.09</ci_lower_limit>
            <ci_upper_limit>6.45</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>5.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.65</ci_lower_limit>
            <ci_upper_limit>7.75</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>3.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.49</ci_lower_limit>
            <ci_upper_limit>4.28</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4</title>
        <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
        <time_frame>Baseline (Visit 1), Day 7 (Visit 4)</time_frame>
        <population>Evaluable Immunogenicity population; GMCs calculated using all participants with available data at both the prevaccination and postvaccination blood draws.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC Prevaccination Visit 1</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC / 13vPnC Postvaccination Visit 4</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4</title>
          <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
          <population>Evaluable Immunogenicity population; GMCs calculated using all participants with available data at both the prevaccination and postvaccination blood draws.</population>
          <units>Mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="0.12" upper_limit="0.33"/>
                    <measurement group_id="O2" value="3.21" lower_limit="2.10" upper_limit="4.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.89" lower_limit="4.61" upper_limit="7.51"/>
                    <measurement group_id="O2" value="29.46" lower_limit="20.74" upper_limit="41.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" lower_limit="1.19" upper_limit="2.00"/>
                    <measurement group_id="O2" value="5.96" lower_limit="4.57" upper_limit="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" lower_limit="0.39" upper_limit="0.86"/>
                    <measurement group_id="O2" value="10.25" lower_limit="6.85" upper_limit="15.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.48" upper_limit="1.18"/>
                    <measurement group_id="O2" value="3.17" lower_limit="2.26" upper_limit="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" lower_limit="2.08" upper_limit="4.15"/>
                    <measurement group_id="O2" value="7.46" lower_limit="5.43" upper_limit="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" lower_limit="1.92" upper_limit="3.27"/>
                    <measurement group_id="O2" value="10.56" lower_limit="7.69" upper_limit="14.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.71" upper_limit="1.54"/>
                    <measurement group_id="O2" value="4.42" lower_limit="2.93" upper_limit="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" lower_limit="0.83" upper_limit="2.04"/>
                    <measurement group_id="O2" value="2.12" lower_limit="1.54" upper_limit="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" lower_limit="2.45" upper_limit="4.27"/>
                    <measurement group_id="O2" value="5.40" lower_limit="4.08" upper_limit="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" lower_limit="2.85" upper_limit="5.03"/>
                    <measurement group_id="O2" value="13.60" lower_limit="9.01" upper_limit="20.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" lower_limit="0.93" upper_limit="2.05"/>
                    <measurement group_id="O2" value="4.70" lower_limit="3.26" upper_limit="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.05" lower_limit="5.52" upper_limit="8.99"/>
                    <measurement group_id="O2" value="13.40" lower_limit="10.30" upper_limit="17.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>15.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.16</ci_lower_limit>
            <ci_upper_limit>27.46</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>5.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.50</ci_lower_limit>
            <ci_upper_limit>7.16</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>3.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.93</ci_lower_limit>
            <ci_upper_limit>5.09</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>17.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.11</ci_lower_limit>
            <ci_upper_limit>27.79</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>4.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.86</ci_lower_limit>
            <ci_upper_limit>6.23</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>2.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.78</ci_lower_limit>
            <ci_upper_limit>3.62</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>4.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.86</ci_lower_limit>
            <ci_upper_limit>6.19</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>4.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.79</ci_lower_limit>
            <ci_upper_limit>6.42</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.30</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.30</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>3.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.39</ci_lower_limit>
            <ci_upper_limit>5.42</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>3.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.42</ci_lower_limit>
            <ci_upper_limit>4.82</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.60</ci_lower_limit>
            <ci_upper_limit>2.26</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4</title>
        <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
        <time_frame>Baseline (Visit 1), Day 7 (Visit 4)</time_frame>
        <population>Evaluable Immunogenicity population; GMCs calculated using all participants with available data at both the prevaccination and postvaccination blood draws. N=number of participants with valid and determinate assay results for both the prevaccination and postvaccination blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>MnCC / 13vPnC Prevaccination Visit 1</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC Postvaccination Visit 4</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4</title>
          <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
          <population>Evaluable Immunogenicity population; GMCs calculated using all participants with available data at both the prevaccination and postvaccination blood draws. N=number of participants with valid and determinate assay results for both the prevaccination and postvaccination blood draw.</population>
          <units>Mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.07" upper_limit="0.29"/>
                    <measurement group_id="O2" value="1.21" lower_limit="0.70" upper_limit="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" lower_limit="2.78" upper_limit="5.67"/>
                    <measurement group_id="O2" value="9.42" lower_limit="6.23" upper_limit="14.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.20" upper_limit="2.38"/>
                    <measurement group_id="O2" value="3.41" lower_limit="2.51" upper_limit="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" lower_limit="0.43" upper_limit="1.43"/>
                    <measurement group_id="O2" value="5.22" lower_limit="2.76" upper_limit="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.46" upper_limit="1.13"/>
                    <measurement group_id="O2" value="3.53" lower_limit="2.16" upper_limit="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" lower_limit="1.32" upper_limit="3.05"/>
                    <measurement group_id="O2" value="5.47" lower_limit="3.51" upper_limit="8.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" lower_limit="1.70" upper_limit="3.14"/>
                    <measurement group_id="O2" value="6.51" lower_limit="4.24" upper_limit="10.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" lower_limit="0.43" upper_limit="1.15"/>
                    <measurement group_id="O2" value="2.65" lower_limit="1.75" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="0.67" upper_limit="1.82"/>
                    <measurement group_id="O2" value="1.46" lower_limit="0.97" upper_limit="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" lower_limit="2.77" upper_limit="5.31"/>
                    <measurement group_id="O2" value="5.00" lower_limit="3.49" upper_limit="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" lower_limit="2.79" upper_limit="5.23"/>
                    <measurement group_id="O2" value="7.79" lower_limit="5.17" upper_limit="11.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="0.73" upper_limit="1.72"/>
                    <measurement group_id="O2" value="3.21" lower_limit="2.25" upper_limit="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.18" lower_limit="4.57" upper_limit="8.35"/>
                    <measurement group_id="O2" value="12.03" lower_limit="8.83" upper_limit="16.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>8.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.50</ci_lower_limit>
            <ci_upper_limit>15.56</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>2.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.78</ci_lower_limit>
            <ci_upper_limit>3.16</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>2.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.63</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>6.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.31</ci_lower_limit>
            <ci_upper_limit>10.15</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>4.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.34</ci_lower_limit>
            <ci_upper_limit>7.26</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>2.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.08</ci_lower_limit>
            <ci_upper_limit>3.57</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>2.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.08</ci_lower_limit>
            <ci_upper_limit>3.83</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>3.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.80</ci_lower_limit>
            <ci_upper_limit>5.13</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.51</ci_lower_limit>
            <ci_upper_limit>2.75</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>2.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.19</ci_lower_limit>
            <ci_upper_limit>3.77</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>1.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.59</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5</title>
        <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
        <time_frame>Baseline (Visit 1), Day 28 (Visit 5)</time_frame>
        <population>Evaluable Immunogenicity population; GMTs calculated using all participants with available data at both the prevaccination and postvaccination blood draws.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC Prevaccination Visit 1</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC / 13vPnC Postvaccination Visit 5</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5</title>
          <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
          <population>Evaluable Immunogenicity population; GMTs calculated using all participants with available data at both the prevaccination and postvaccination blood draws.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="6.3" upper_limit="80.7"/>
                    <measurement group_id="O2" value="4535" lower_limit="2836.5" upper_limit="7251.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1024" lower_limit="488.4" upper_limit="2148.4"/>
                    <measurement group_id="O2" value="11939" lower_limit="8748.1" upper_limit="16293.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="13.4" upper_limit="137.3"/>
                    <measurement group_id="O2" value="6709" lower_limit="5097.5" upper_limit="8829.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159" lower_limit="63.7" upper_limit="396.0"/>
                    <measurement group_id="O2" value="5946" lower_limit="4361.1" upper_limit="8107.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="19.5" upper_limit="149.5"/>
                    <measurement group_id="O2" value="5067" lower_limit="3375.1" upper_limit="7607.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="15.1" upper_limit="73.3"/>
                    <measurement group_id="O2" value="1623" lower_limit="995.2" upper_limit="2647.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="34.1" upper_limit="223.4"/>
                    <measurement group_id="O2" value="2799" lower_limit="2048.5" upper_limit="3823.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4.3" upper_limit="7.4"/>
                    <measurement group_id="O2" value="440" lower_limit="301.8" upper_limit="641.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="6.9" upper_limit="16.6"/>
                    <measurement group_id="O2" value="111" lower_limit="87.1" upper_limit="141.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3.6" upper_limit="5.6"/>
                    <measurement group_id="O2" value="277" lower_limit="145.2" upper_limit="526.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="7.1" upper_limit="39.7"/>
                    <measurement group_id="O2" value="9029" lower_limit="6255.0" upper_limit="13034.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="17.7" upper_limit="205.3"/>
                    <measurement group_id="O2" value="7036" lower_limit="4886.0" upper_limit="10131.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="36.7" upper_limit="157.5"/>
                    <measurement group_id="O2" value="1869" lower_limit="1099.8" upper_limit="3177.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>201.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>55.11</ci_lower_limit>
            <ci_upper_limit>739.05</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>11.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.20</ci_lower_limit>
            <ci_upper_limit>26.10</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>156.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>48.72</ci_lower_limit>
            <ci_upper_limit>501.86</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>37.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.71</ci_lower_limit>
            <ci_upper_limit>102.31</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>93.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>30.99</ci_lower_limit>
            <ci_upper_limit>284.31</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>48.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.27</ci_lower_limit>
            <ci_upper_limit>101.97</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>32.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.99</ci_lower_limit>
            <ci_upper_limit>85.81</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>78.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>50.42</ci_lower_limit>
            <ci_upper_limit>120.94</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>10.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.80</ci_lower_limit>
            <ci_upper_limit>15.72</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>61.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>32.75</ci_lower_limit>
            <ci_upper_limit>116.34</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>536.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>212.04</ci_lower_limit>
            <ci_upper_limit>1357.19</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>116.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>33.28</ci_lower_limit>
            <ci_upper_limit>410.33</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>24.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.30</ci_lower_limit>
            <ci_upper_limit>53.42</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5</title>
        <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
        <time_frame>Baseline (Visit 1), Day 28 (Visit 5)</time_frame>
        <population>Evaluable Immunogenicity population; GMTs calculated using all participants with available data at both the prevaccination and postvaccination blood draws. N=number of participants with valid and determinate assay results for both the prevaccination and postvaccination blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>MnCC / 13vPnC Prevaccination Visit 1</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC Postvaccination Visit 5</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 5</title>
          <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
          <population>Evaluable Immunogenicity population; GMTs calculated using all participants with available data at both the prevaccination and postvaccination blood draws. N=number of participants with valid and determinate assay results for both the prevaccination and postvaccination blood draw.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="4.5" upper_limit="174.3"/>
                    <measurement group_id="O2" value="4704" lower_limit="2958.0" upper_limit="7481.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288" lower_limit="74.8" upper_limit="1106.9"/>
                    <measurement group_id="O2" value="11607" lower_limit="7762.6" upper_limit="17354.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="37.9" upper_limit="382.8"/>
                    <measurement group_id="O2" value="7457" lower_limit="5702.3" upper_limit="9751.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262" lower_limit="98.1" upper_limit="700.5"/>
                    <measurement group_id="O2" value="7006" lower_limit="4997.7" upper_limit="9822.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="8.4" upper_limit="75.7"/>
                    <measurement group_id="O2" value="5736" lower_limit="4141.4" upper_limit="7943.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="10.5" upper_limit="50.6"/>
                    <measurement group_id="O2" value="2696" lower_limit="1831.0" upper_limit="3968.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="5.0" upper_limit="23.5"/>
                    <measurement group_id="O2" value="5197" lower_limit="3599.2" upper_limit="7503.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="341" lower_limit="221.9" upper_limit="524.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="7.0" upper_limit="18.2"/>
                    <measurement group_id="O2" value="98" lower_limit="75.2" upper_limit="126.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3.7" upper_limit="5.0"/>
                    <measurement group_id="O2" value="336" lower_limit="175.4" upper_limit="642.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="8.9" upper_limit="64.2"/>
                    <measurement group_id="O2" value="10488" lower_limit="7460.6" upper_limit="14744.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="21.1" upper_limit="275.2"/>
                    <measurement group_id="O2" value="6098" lower_limit="4392.9" upper_limit="8464.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="19.9" upper_limit="78.1"/>
                    <measurement group_id="O2" value="2424" lower_limit="1696.6" upper_limit="3462.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>168.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.22</ci_lower_limit>
            <ci_upper_limit>1409.76</ci_upper_limit>
            <estimate_desc>CI for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: GMRFs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>40.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.97</ci_lower_limit>
            <ci_upper_limit>148.44</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>61.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.83</ci_lower_limit>
            <ci_upper_limit>203.72</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>26.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.67</ci_lower_limit>
            <ci_upper_limit>73.84</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>226.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>79.81</ci_lower_limit>
            <ci_upper_limit>645.29</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>116.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>54.54</ci_lower_limit>
            <ci_upper_limit>250.13</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>481.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>207.01</ci_lower_limit>
            <ci_upper_limit>1117.69</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>66.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>41.80</ci_lower_limit>
            <ci_upper_limit>105.75</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>8.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.36</ci_lower_limit>
            <ci_upper_limit>13.94</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>78.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>41.38</ci_lower_limit>
            <ci_upper_limit>147.80</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>438.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>169.52</ci_lower_limit>
            <ci_upper_limit>1132.43</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>80.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.28</ci_lower_limit>
            <ci_upper_limit>274.82</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: GMFRs were calculated (postvaccination Visit 5 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>61.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>28.73</ci_lower_limit>
            <ci_upper_limit>131.76</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4</title>
        <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
        <time_frame>Baseline (Visit 1), Day 7 (Visit 4)</time_frame>
        <population>Evaluable Immunogenicity population; GMTs calculated using all participants with available data at both the prevaccination and postvaccination blood draws. N=number of participants with valid and determinate assay results for both the prevaccination and postvaccination blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC Prevaccination Visit 1</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC / 13vPnC Postvaccination Visit 4</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to 7vPnC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4</title>
          <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
          <population>Evaluable Immunogenicity population; GMTs calculated using all participants with available data at both the prevaccination and postvaccination blood draws. N=number of participants with valid and determinate assay results for both the prevaccination and postvaccination blood draw.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="6.0" upper_limit="62.8"/>
                    <measurement group_id="O2" value="5449" lower_limit="3118.6" upper_limit="9519.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1034" lower_limit="505.1" upper_limit="2116.9"/>
                    <measurement group_id="O2" value="7885" lower_limit="5792.0" upper_limit="10734.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="13.4" upper_limit="137.3"/>
                    <measurement group_id="O2" value="6497" lower_limit="4357.4" upper_limit="9687.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148" lower_limit="58.2" upper_limit="375.7"/>
                    <measurement group_id="O2" value="3497" lower_limit="2440.8" upper_limit="5009.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="20.6" upper_limit="163.8"/>
                    <measurement group_id="O2" value="5922" lower_limit="3784.0" upper_limit="9268.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="17.4" upper_limit="91.6"/>
                    <measurement group_id="O2" value="1243" lower_limit="620.6" upper_limit="2489.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="31.4" upper_limit="201.3"/>
                    <measurement group_id="O2" value="1487" lower_limit="884.7" upper_limit="2499.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4.3" upper_limit="7.6"/>
                    <measurement group_id="O2" value="367" lower_limit="228.8" upper_limit="587.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="6.9" upper_limit="16.6"/>
                    <measurement group_id="O2" value="119" lower_limit="82.1" upper_limit="172.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3.6" upper_limit="5.6"/>
                    <measurement group_id="O2" value="185" lower_limit="100.9" upper_limit="337.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="7.1" upper_limit="39.7"/>
                    <measurement group_id="O2" value="8072" lower_limit="5195.8" upper_limit="12538.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="17.7" upper_limit="205.3"/>
                    <measurement group_id="O2" value="4601" lower_limit="2998.3" upper_limit="7060.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="36.7" upper_limit="157.5"/>
                    <measurement group_id="O2" value="1345" lower_limit="767.4" upper_limit="2357.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>281.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>76.65</ci_lower_limit>
            <ci_upper_limit>1035.49</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>7.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.47</ci_lower_limit>
            <ci_upper_limit>16.75</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>151.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>42.01</ci_lower_limit>
            <ci_upper_limit>545.84</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>23.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.67</ci_lower_limit>
            <ci_upper_limit>64.54</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>102.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>32.00</ci_lower_limit>
            <ci_upper_limit>325.40</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>31.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.71</ci_lower_limit>
            <ci_upper_limit>76.13</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>18.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.82</ci_lower_limit>
            <ci_upper_limit>51.39</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>64.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>37.33</ci_lower_limit>
            <ci_upper_limit>111.18</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>11.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.64</ci_lower_limit>
            <ci_upper_limit>18.52</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>41.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.09</ci_lower_limit>
            <ci_upper_limit>73.48</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>479.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>171.63</ci_lower_limit>
            <ci_upper_limit>1339.96</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>76.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.63</ci_lower_limit>
            <ci_upper_limit>270.02</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>17.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.61</ci_lower_limit>
            <ci_upper_limit>41.08</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4</title>
        <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
        <time_frame>Baseline (Visit 1), Day 7 (Visit 4)</time_frame>
        <population>Evaluable Immunogenicity population; GMTs calculated using all participants with available data at both the prevaccination and postvaccination blood draws. N=number of participants with valid and determinate assay results for both the prevaccination and postvaccination blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>MnCC / 13vPnC Prevaccination Visit 1</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC Postvaccination Visit 4</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal Opsonophagocytic Activity (OPA) Assay Geometric Mean Titers (GMTs) for the 13 Serotypes Relative to MnCC / 13vPnC Prevaccination Visit 1 and Postvaccination Visit 4</title>
          <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
          <population>Evaluable Immunogenicity population; GMTs calculated using all participants with available data at both the prevaccination and postvaccination blood draws. N=number of participants with valid and determinate assay results for both the prevaccination and postvaccination blood draw.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="6.3" upper_limit="254.0"/>
                    <measurement group_id="O2" value="6782" lower_limit="3687.6" upper_limit="12471.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405" lower_limit="103.5" upper_limit="1584.7"/>
                    <measurement group_id="O2" value="7195" lower_limit="4585.5" upper_limit="11289.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" lower_limit="36.8" upper_limit="364.9"/>
                    <measurement group_id="O2" value="7855" lower_limit="5532.9" upper_limit="11152.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280" lower_limit="103.1" upper_limit="760.7"/>
                    <measurement group_id="O2" value="6209" lower_limit="4253.9" upper_limit="9063.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="8.4" upper_limit="75.7"/>
                    <measurement group_id="O2" value="5193" lower_limit="3658.1" upper_limit="7372.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="9.4" upper_limit="44.7"/>
                    <measurement group_id="O2" value="1855" lower_limit="1055.8" upper_limit="3258.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="5.0" upper_limit="23.5"/>
                    <measurement group_id="O2" value="991" lower_limit="501.3" upper_limit="1959.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="385" lower_limit="249.4" upper_limit="595.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="7.2" upper_limit="19.0"/>
                    <measurement group_id="O2" value="101" lower_limit="72.2" upper_limit="141.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3.7" upper_limit="5.0"/>
                    <measurement group_id="O2" value="258" lower_limit="132.3" upper_limit="503.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="8.7" upper_limit="59.1"/>
                    <measurement group_id="O2" value="6107" lower_limit="4149.7" upper_limit="8987.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="24.7" upper_limit="363.8"/>
                    <measurement group_id="O2" value="3577" lower_limit="1774.8" upper_limit="7208.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="19.9" upper_limit="78.1"/>
                    <measurement group_id="O2" value="1763" lower_limit="1220.1" upper_limit="2547.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>170.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.24</ci_lower_limit>
            <ci_upper_limit>1301.79</ci_upper_limit>
            <estimate_desc>CI for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: GMRFs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>17.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.27</ci_lower_limit>
            <ci_upper_limit>59.91</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>67.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.45</ci_lower_limit>
            <ci_upper_limit>249.02</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>22.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.94</ci_lower_limit>
            <ci_upper_limit>61.88</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>205.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>70.04</ci_lower_limit>
            <ci_upper_limit>602.78</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>90.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>40.28</ci_lower_limit>
            <ci_upper_limit>203.27</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>91.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36.25</ci_lower_limit>
            <ci_upper_limit>232.13</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>75.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>47.32</ci_lower_limit>
            <ci_upper_limit>120.91</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>8.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.21</ci_lower_limit>
            <ci_upper_limit>14.40</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>60.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.06</ci_lower_limit>
            <ci_upper_limit>115.92</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>269.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>105.09</ci_lower_limit>
            <ci_upper_limit>692.60</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>37.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.85</ci_lower_limit>
            <ci_upper_limit>131.09</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: GMFRs were calculated (postvaccination Visit 4 / prevaccination Visit 1) using all participants with available data from both the prevaccination and postvaccination blood draws.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean fold rise</param_type>
            <param_value>44.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.31</ci_lower_limit>
            <ci_upper_limit>94.01</ci_upper_limit>
            <estimate_desc>CIs for the GMRFs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the mean fold rise.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 5)</title>
        <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
        <time_frame>Day 28 (Visit 5)</time_frame>
        <population>Evaluable Immunogenicity population; GMCs were calculated using all participants with available data for the specified blood draw. N=number of participants with a determinate OPA antibody concentration for the serotypes.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 5)</title>
          <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
          <population>Evaluable Immunogenicity population; GMCs were calculated using all participants with available data for the specified blood draw. N=number of participants with a determinate OPA antibody concentration for the serotypes.</population>
          <units>Mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.73" lower_limit="4.21" upper_limit="7.81"/>
                    <measurement group_id="O2" value="2.92" lower_limit="2.22" upper_limit="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.72" lower_limit="50.19" upper_limit="88.70"/>
                    <measurement group_id="O2" value="22.62" lower_limit="14.56" upper_limit="35.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.72" lower_limit="6.68" upper_limit="11.40"/>
                    <measurement group_id="O2" value="4.70" lower_limit="3.49" upper_limit="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.45" lower_limit="27.72" upper_limit="61.97"/>
                    <measurement group_id="O2" value="18.50" lower_limit="10.10" upper_limit="33.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.72" lower_limit="4.18" upper_limit="7.82"/>
                    <measurement group_id="O2" value="9.04" lower_limit="5.98" upper_limit="13.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.17" lower_limit="9.54" upper_limit="21.07"/>
                    <measurement group_id="O2" value="15.80" lower_limit="10.00" upper_limit="24.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.20" lower_limit="12.44" upper_limit="23.77"/>
                    <measurement group_id="O2" value="20.80" lower_limit="13.07" upper_limit="33.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.55" lower_limit="6.46" upper_limit="14.13"/>
                    <measurement group_id="O2" value="5.63" lower_limit="3.67" upper_limit="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" lower_limit="1.58" upper_limit="2.87"/>
                    <measurement group_id="O2" value="1.71" lower_limit="1.20" upper_limit="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.80" lower_limit="4.75" upper_limit="9.74"/>
                    <measurement group_id="O2" value="7.52" lower_limit="5.12" upper_limit="11.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.11" lower_limit="19.04" upper_limit="44.50"/>
                    <measurement group_id="O2" value="16.08" lower_limit="10.18" upper_limit="25.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.92" lower_limit="7.03" upper_limit="14.01"/>
                    <measurement group_id="O2" value="5.75" lower_limit="3.98" upper_limit="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.29" lower_limit="14.90" upper_limit="30.43"/>
                    <measurement group_id="O2" value="20.17" lower_limit="15.28" upper_limit="26.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.31</ci_lower_limit>
            <ci_upper_limit>2.95</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>2.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.78</ci_lower_limit>
            <ci_upper_limit>4.90</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>2.75</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>2.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>4.53</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>3.00</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>3.34</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>2.83</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 4)</title>
        <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
        <time_frame>Day 7 (Visit 4)</time_frame>
        <population>Evaluable Immunogenicity population; GMCs were calculated using all participants with available data for the specified blood draw. N=number of participants with a determinate OPA antibody concentration for the serotypes.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 4)</title>
          <description>Pneumococcal IgG GMCs measured as Mcg/mL for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
          <population>Evaluable Immunogenicity population; GMCs were calculated using all participants with available data for the specified blood draw. N=number of participants with a determinate OPA antibody concentration for the serotypes.</population>
          <units>Mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.07" upper_limit="4.35"/>
                    <measurement group_id="O2" value="1.37" lower_limit="0.90" upper_limit="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.46" lower_limit="20.74" upper_limit="41.86"/>
                    <measurement group_id="O2" value="9.42" lower_limit="6.23" upper_limit="14.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" lower_limit="4.40" upper_limit="7.51"/>
                    <measurement group_id="O2" value="3.41" lower_limit="2.51" upper_limit="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.25" lower_limit="6.85" upper_limit="15.33"/>
                    <measurement group_id="O2" value="5.22" lower_limit="2.76" upper_limit="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" lower_limit="2.22" upper_limit="4.29"/>
                    <measurement group_id="O2" value="3.45" lower_limit="2.16" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.66" lower_limit="5.66" upper_limit="10.36"/>
                    <measurement group_id="O2" value="4.85" lower_limit="3.09" upper_limit="7.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.56" lower_limit="7.69" upper_limit="14.51"/>
                    <measurement group_id="O2" value="6.51" lower_limit="4.24" upper_limit="10.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" lower_limit="2.82" upper_limit="5.62"/>
                    <measurement group_id="O2" value="2.83" lower_limit="1.86" upper_limit="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="1.48" upper_limit="2.76"/>
                    <measurement group_id="O2" value="1.40" lower_limit="0.95" upper_limit="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.40" lower_limit="4.08" upper_limit="7.15"/>
                    <measurement group_id="O2" value="5.12" lower_limit="3.60" upper_limit="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.60" lower_limit="9.01" upper_limit="20.53"/>
                    <measurement group_id="O2" value="7.25" lower_limit="4.75" upper_limit="11.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.70" lower_limit="3.26" upper_limit="6.78"/>
                    <measurement group_id="O2" value="3.17" lower_limit="2.24" upper_limit="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.40" lower_limit="10.30" upper_limit="17.42"/>
                    <measurement group_id="O2" value="12.03" lower_limit="8.83" upper_limit="16.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>3.79</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>3.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.84</ci_lower_limit>
            <ci_upper_limit>5.32</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>2.51</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>4.07</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>2.66</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>2.73</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>2.34</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6A: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>3.35</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>2.44</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean concentrations</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 5)</title>
        <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
        <time_frame>Day 28 (Visit 5)</time_frame>
        <population>Evaluable Immunogenicity population; GMTs were calculated using all participants with available data for the specified blood draw. N=number of participants with a determinate OPA antibody titer for the serotypes.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 5)</title>
          <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
          <population>Evaluable Immunogenicity population; GMTs were calculated using all participants with available data for the specified blood draw. N=number of participants with a determinate OPA antibody titer for the serotypes.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4626" lower_limit="3322.5" upper_limit="6441.2"/>
                    <measurement group_id="O2" value="6065" lower_limit="4590.9" upper_limit="8012.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11451" lower_limit="8290.4" upper_limit="15817.9"/>
                    <measurement group_id="O2" value="10380" lower_limit="7515.2" upper_limit="14336.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6346" lower_limit="5152.2" upper_limit="7817.5"/>
                    <measurement group_id="O2" value="7555" lower_limit="5916.7" upper_limit="9646.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5898" lower_limit="4481.0" upper_limit="7762.1"/>
                    <measurement group_id="O2" value="7031" lower_limit="5195.6" upper_limit="9515.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5090" lower_limit="3428.4" upper_limit="7557.7"/>
                    <measurement group_id="O2" value="6005" lower_limit="4389.3" upper_limit="8214.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1623" lower_limit="995.2" upper_limit="2647.9"/>
                    <measurement group_id="O2" value="2696" lower_limit="1831.0" upper_limit="3968.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2752" lower_limit="2074.6" upper_limit="3651.3"/>
                    <measurement group_id="O2" value="4841" lower_limit="3574.5" upper_limit="6555.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="449" lower_limit="312.8" upper_limit="643.2"/>
                    <measurement group_id="O2" value="347" lower_limit="228.3" upper_limit="527.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" lower_limit="89.2" upper_limit="143.5"/>
                    <measurement group_id="O2" value="99" lower_limit="77.0" upper_limit="126.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296" lower_limit="158.8" upper_limit="549.9"/>
                    <measurement group_id="O2" value="336" lower_limit="175.4" upper_limit="642.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9458" lower_limit="6674.2" upper_limit="13404.0"/>
                    <measurement group_id="O2" value="10842" lower_limit="7904.9" upper_limit="14870.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6740" lower_limit="4933.2" upper_limit="9207.7"/>
                    <measurement group_id="O2" value="6050" lower_limit="4515.0" upper_limit="8106.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2120" lower_limit="1308.0" upper_limit="3435.3"/>
                    <measurement group_id="O2" value="2340" lower_limit="1667.0" upper_limit="3285.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: ratio of GMTs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: ratio of GMTs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: ratio of GMTs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>2.22</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>2.13</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 4)</title>
        <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
        <time_frame>Day 7 (Visit 4)</time_frame>
        <population>Evaluable Immunogenicity population; GMTs were calculated using all participants with available data for the specified blood draw. N=number of participants with a determinate OPA antibody titer for the serotypes.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes for 7vPnC / 13vPnC Relative to MnCC / 13vPnC After Vaccination (Visit 4)</title>
          <description>Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A). The 2-sided, 95% CIs for the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.</description>
          <population>Evaluable Immunogenicity population; GMTs were calculated using all participants with available data for the specified blood draw. N=number of participants with a determinate OPA antibody titer for the serotypes.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5567" lower_limit="3202.5" upper_limit="9678.7"/>
                    <measurement group_id="O2" value="8339" lower_limit="6154.1" upper_limit="11299.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8082" lower_limit="5743.5" upper_limit="11372.6"/>
                    <measurement group_id="O2" value="6450" lower_limit="4477.8" upper_limit="9290.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6865" lower_limit="4826.7" upper_limit="9763.7"/>
                    <measurement group_id="O2" value="7806" lower_limit="5491.4" upper_limit="11095.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3596" lower_limit="2613.0" upper_limit="4948.5"/>
                    <measurement group_id="O2" value="5994" lower_limit="4246.9" upper_limit="8460.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5833" lower_limit="3770.5" upper_limit="9023.7"/>
                    <measurement group_id="O2" value="5266" lower_limit="3779.3" upper_limit="7338.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1243" lower_limit="620.6" upper_limit="2489.8"/>
                    <measurement group_id="O2" value="1855" lower_limit="1055.8" upper_limit="3258.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1575" lower_limit="987.7" upper_limit="2511.7"/>
                    <measurement group_id="O2" value="1141" lower_limit="655.1" upper_limit="1986.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379" lower_limit="241.8" upper_limit="594.9"/>
                    <measurement group_id="O2" value="393" lower_limit="257.2" upper_limit="600.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" lower_limit="81.3" upper_limit="167.5"/>
                    <measurement group_id="O2" value="104" lower_limit="75.4" upper_limit="143.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200" lower_limit="111.2" upper_limit="358.6"/>
                    <measurement group_id="O2" value="258" lower_limit="132.3" upper_limit="503.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8534" lower_limit="5631.9" upper_limit="12931.6"/>
                    <measurement group_id="O2" value="6199" lower_limit="4357.6" upper_limit="8818.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4750" lower_limit="3291.8" upper_limit="6852.9"/>
                    <measurement group_id="O2" value="3760" lower_limit="2106.7" upper_limit="6709.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1504" lower_limit="911.2" upper_limit="2484.1"/>
                    <measurement group_id="O2" value="1761" lower_limit="1242.8" upper_limit="2496.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: ratio of GMTs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: ratio of GMTs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>2.81</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>2.44</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: ratio of GMCs for (7vPnC/13vPnC) relative to (MnCC/13vPnC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of geometric mean titers</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
            <estimate_desc>CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(7vPnC/13vPnC) – (MnCC/13vPnC)].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 4 Days After Vaccination</title>
        <description>Local reactions reported using the diary card during the 4-day reactogenicity period after vaccination. Tenderness at injection site scaled as Any (tenderness present) or Significant (present and interfered with limb movement). Redness and swelling at injection site scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); or Severe (&gt; 7.0 cm). Participants may be represented in &gt;1 category.</description>
        <time_frame>Baseline up to 4 days after vaccination on Day 1</time_frame>
        <population>Safety population included all participants who received the vaccine. N=number of participants with analyzable data for reactogenicity events (reported Yes for at least 1 day or No for all days).</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions Within 4 Days After Vaccination</title>
          <description>Local reactions reported using the diary card during the 4-day reactogenicity period after vaccination. Tenderness at injection site scaled as Any (tenderness present) or Significant (present and interfered with limb movement). Redness and swelling at injection site scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); or Severe (&gt; 7.0 cm). Participants may be represented in &gt;1 category.</description>
          <population>Safety population included all participants who received the vaccine. N=number of participants with analyzable data for reactogenicity events (reported Yes for at least 1 day or No for all days).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1"/>
                    <measurement group_id="O2" value="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 4 Days After Vaccination</title>
        <description>Systemic events reported using the diary card during the 4-day reactogenicity period after vaccination. Temperature scaled as Fever ≥38 but ≤39 degrees Celsius (C) (mild), &gt;39 but ≤40 degrees C (moderate), or &gt;40 degrees C (severe). Presence of Decreased appetite, Irritability, Increased sleep, Decreased sleep, Rash, and Hives; also scaled as Mild (easily tolerated, minimal discomfort; not interfering with activities), Moderate (sufficiently discomforting to interfere with normal activities), or Severe (may prevent normal activities and require medical intervention).</description>
        <time_frame>Baseline up to 4 days after vaccination on Day 1</time_frame>
        <population>Safety population; N=number of participants with analyzable data for reactogenicity events (reported Yes for at least 1 day or No for all days).</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events Within 4 Days After Vaccination</title>
          <description>Systemic events reported using the diary card during the 4-day reactogenicity period after vaccination. Temperature scaled as Fever ≥38 but ≤39 degrees Celsius (C) (mild), &gt;39 but ≤40 degrees C (moderate), or &gt;40 degrees C (severe). Presence of Decreased appetite, Irritability, Increased sleep, Decreased sleep, Rash, and Hives; also scaled as Mild (easily tolerated, minimal discomfort; not interfering with activities), Moderate (sufficiently discomforting to interfere with normal activities), or Severe (may prevent normal activities and require medical intervention).</description>
          <population>Safety population; N=number of participants with analyzable data for reactogenicity events (reported Yes for at least 1 day or No for all days).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 but ≤39 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                    <measurement group_id="O2" value="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8"/>
                    <measurement group_id="O2" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥1:8 for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)</title>
        <description>Percentage of participants achieving predefined OPA antibody titer ≥1:8 for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. The lowest titer that can be determined using the standard OPA assay is a titer of 1:8 limit of detection (LOD) and is the same for each serotype-specific OPA assay.</description>
        <time_frame>Day 28 (Visit 5)</time_frame>
        <population>Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the serotypes.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥1:8 for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 5)</title>
          <description>Percentage of participants achieving predefined OPA antibody titer ≥1:8 for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. The lowest titer that can be determined using the standard OPA assay is a titer of 1:8 limit of detection (LOD) and is the same for each serotype-specific OPA assay.</description>
          <population>Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the serotypes.</population>
          <units>observed percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="86.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="94.3" lower_limit="80.8" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.2</ci_lower_limit>
            <ci_upper_limit>10.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>17.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥1:8 for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)</title>
        <description>Percentage of participants achieving predefined OPA antibody titer ≥1:8 for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. The lowest titer that can be determined using the standard OPA assay is a titer of 1:8 limit of detection (LOD) and is the same for each serotype-specific OPA assay.</description>
        <time_frame>Day 7 (Visit 4)</time_frame>
        <population>Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the serotypes.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.</description>
          </group>
          <group group_id="O2">
            <title>MnCC / 13vPnC</title>
            <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Pneumococcal Opsonophagocytic Activity (OPA) Antibody Titer ≥1:8 for the 13 Serotypes for 7vPnC / 13vPnC in Comparison to MnCC / 13vPnC After Vaccination (Visit 4)</title>
          <description>Percentage of participants achieving predefined OPA antibody titer ≥1:8 for the 13 pneumococcal serotypes (7vPnC serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and additional serotypes 1, 3, 5, 6A, 7F, and 19A) along with the exact, 2-sided 95% CIs based on the observed percentage of participants. The lowest titer that can be determined using the standard OPA assay is a titer of 1:8 limit of detection (LOD) and is the same for each serotype-specific OPA assay.</description>
          <population>Evaluable Immunogenicity population; N=number of participants with a determinate OPA antibody titer to the serotypes.</population>
          <units>observed percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7vPnC serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="86.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7vPnC serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" lower_limit="85.8" upper_limit="99.9"/>
                    <measurement group_id="O2" value="94.3" lower_limit="80.8" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="86.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="94.1" lower_limit="80.3" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 4: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.9</ci_lower_limit>
            <ci_upper_limit>8.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 6B: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.2</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 9V: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 14: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 18C: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 19F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.1</ci_lower_limit>
            <ci_upper_limit>10.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>7vPnC serotype 23F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>16.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 1: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 3: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 5: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.6</ci_lower_limit>
            <ci_upper_limit>17.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 6A: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 7F: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.7</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Additional serotype 19A: difference in proportions, [(7vPnC/13vPnC) – (MnCC/13vPnC)], expressed as a percentage, along with exact 2-sided confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Day 4 after vaccination for local reactions and systemic events or up to Day 194 (Visit 6 / Days 166 to 194 Follow-up Telephone Visit to assess AEs)</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 subject and as nonserious in another subject, or 1 subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>7vPnC / 13vPnC</title>
          <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received 7vPnC in study D118-P8.
Adverse Events include Local reactions and Systemic events collected on the diary card and reported in the diary-related case report form (systematic assessment) and other Adverse Events collected on the case report form (non-systematic methods).
Other Adverse Events N=22; Local reactions N=38; Systemic events N=38.</description>
        </group>
        <group group_id="E2">
          <title>MnCC / 13vPnC</title>
          <description>13vPnC administered as a single 0.5 mL dose IM. Participants had previously received MnCC in study D118-P8.
Adverse Events include Local reactions and Systemic events collected on the diary card and reported in the diary-related case report form (systematic assessment) and other Adverse Events collected on the case report form (non-systematic methods).
Other Adverse Events N=20; Local reactions N=36; Systemic events N=36.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphoid tissue hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital flat feet</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Ear congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Fever ≥38 degrees C but ≤39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Decreased appetite: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Decreased appetite: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Irritability: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Irritability: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Increased sleep: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Increased sleep: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Increased sleep: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Decreased sleep: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Decreased sleep: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Systemic Event">Rash: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Patellofemoral pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Tenderness: Any</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Tenderness: Significant</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Swelling: Any</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Swelling: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Swelling: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Redness: Any</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Redness: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="Local Reaction">Redness: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

